IMMUNOPRECISE ANTIBODIES LTD (IPA)
CA45257F2008 - Common Stock
We assign a fundamental rating of 2 out of 10 to IPA. IPA was compared to 55 industry peers in the Life Sciences Tools & Services industry. IPA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IPA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
IPA had negative earnings in the past year.
IPA had a negative operating cash flow in the past year.
IPA had negative earnings in each of the past 5 years.
IPA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IPA has a worse Return On Assets (-46.55%) than 90.91% of its industry peers.
Looking at the Return On Equity, with a value of -84.03%, IPA is doing worse than 78.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.55% | ||
| ROE | -84.03% | ||
| ROIC | N/A |
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 48.21%, IPA is in line with its industry, outperforming 58.18% of the companies in the same industry.
IPA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IPA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
2. Health
2.1 Basic Checks
IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IPA has been increased compared to 5 years ago.
IPA has a worse debt/assets ratio than last year.
2.2 Solvency
IPA has an Altman-Z score of -2.52. This is a bad value and indicates that IPA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IPA (-2.52) is worse than 85.45% of its industry peers.
IPA has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.44, IPA perfoms like the industry average, outperforming 41.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.52 |
ROIC/WACCN/A
WACC9.76%
2.3 Liquidity
IPA has a Current Ratio of 0.99. This is a bad value and indicates that IPA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of IPA (0.99) is worse than 89.09% of its industry peers.
A Quick Ratio of 0.82 indicates that IPA may have some problems paying its short term obligations.
IPA has a Quick ratio of 0.82. This is amonst the worse of the industry: IPA underperforms 83.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
IPA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.05%, which is quite impressive.
Looking at the last year, IPA shows a quite strong growth in Revenue. The Revenue has grown by 11.22% in the last year.
IPA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.55% yearly.
EPS 1Y (TTM)44.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
Revenue 1Y (TTM)11.22%
Revenue growth 3Y11.03%
Revenue growth 5Y17.55%
Sales Q2Q%-7.47%
3.2 Future
The Earnings Per Share is expected to grow by 28.10% on average over the next years. This is a very strong growth
Based on estimates for the next years, IPA will show a very strong growth in Revenue. The Revenue will grow by 22.33% on average per year.
EPS Next Y-2.1%
EPS Next 2Y23.16%
EPS Next 3Y25.06%
EPS Next 5Y28.1%
Revenue Next Year3%
Revenue Next 2Y18.2%
Revenue Next 3Y19.16%
Revenue Next 5Y22.33%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Also next year IPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IPA's earnings are expected to grow with 25.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.16%
EPS Next 3Y25.06%
5. Dividend
5.1 Amount
No dividends for IPA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNOPRECISE ANTIBODIES LTD
NASDAQ:IPA (11/22/2024, 6:13:49 PM)
After market: 0.393 +0.02 (+4.52%)0.376
+0.03 (+7.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.55% | ||
| ROE | -84.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.21% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)44.05%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.22%
Revenue growth 3Y11.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y